BioScrip Inc. (NASDAQ:BIOS)’s share price shot up 1.9% on Thursday . The company traded as high as $2.70 and last traded at $2.65, with a volume of 308,750 shares. The stock had previously closed at $2.60.

Separately, Zacks Investment Research upgraded BioScrip from a “sell” rating to a “hold” rating in a research note on Friday, June 17th.

The firm has a 50-day moving average price of $2.62 and a 200 day moving average price of $2.21. The stock’s market cap is $185.02 million.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by $0.05. The business earned $238.50 million during the quarter, compared to analyst estimates of $232.38 million. The business’s revenue was down 2.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.17) EPS. Equities research analysts expect that BioScrip Inc. will post ($0.20) EPS for the current year.

In related news, Director David W. Golding purchased 12,500 shares of the business’s stock in a transaction on Friday, June 17th. The stock was acquired at an average price of $2.48 per share, for a total transaction of $31,000.00. Following the purchase, the director now owns 42,500 shares of the company’s stock, valued at $105,400. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Coliseum Capital Management, L purchased 4,200,000 shares of the business’s stock in a transaction on Wednesday, June 22nd. The shares were bought at an average price of $2.00 per share, with a total value of $8,400,000.00. The disclosure for this purchase can be found here.

A number of institutional investors recently added to or reduced their stakes in the stock. Gamco Investors INC. ET AL increased its position in BioScrip by 1.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 864,850 shares of the company’s stock worth $1,513,000 after buying an additional 12,250 shares during the period. Diamond Hill Capital Management Inc. increased its position in BioScrip by 2.5% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,055,476 shares of the company’s stock worth $5,347,000 after buying an additional 74,757 shares during the period. Finally, Gabelli Funds LLC increased its position in BioScrip by 22.9% in the fourth quarter. Gabelli Funds LLC now owns 11,430,900 shares of the company’s stock worth $20,004,000 after buying an additional 2,132,060 shares during the period.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.